Loading...
•
Dec 31, 2023
RAPT Q4 2023 Earnings Report
Reported financial results for the fourth quarter and year ended December 31, 2023.
Key Takeaways
RAPT Therapeutics reported a net loss of $30.9 million for the fourth quarter of 2023, compared to a net loss of $23.0 million for the fourth quarter of 2022. The company's cash and cash equivalents and marketable securities totaled $158.9 million as of December 31, 2023.
Net loss for the fourth quarter of 2023 was $30.9 million.
Research and development expenses for the fourth quarter of 2023 were $26.8 million.
General and administrative expenses for the fourth quarter of 2023 were $6.5 million.
Cash and cash equivalents and marketable securities were $158.9 million as of December 31, 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...